Ranc Sylvain, Sibellas Franck, Green Lisa
Unité 51, Hôpital Cardiologique de Lyon, 28 Avenue Doyen Lépine, 69677 BRON Cedex, France.
J Invasive Cardiol. 2013 Jan;25(1):E1-3.
A 58-year-old male patient, suffering from an acute anterior ST-elevated myocardial infarction, developed cardiogenic shock, despite an optimal revascularization and hemodynamic support through the use of an intra-aortic balloon pump and inotropic pharmacological agents. Additional support was provided by a left ventricular assistance device Impella LP 5.0 (Abiomed, Europe GmbH). Device failure occurred 27 hours after implantation due to an acute thrombosis of the Impella inflow portion. This major adverse event might have occurred due to an inflammatory status in the cardiogenic shock context, a pre-existing intraventricular thrombus that could have been sucked up inside the Impella, and/or a subtherapeutic anticoagulation. There are very few data regarding this type of complication. Further studies are therefore needed to assess the frequency of such a complication and the means to avoid it.
一名58岁男性患者，患有急性前壁ST段抬高型心肌梗死，尽管通过使用主动脉内球囊泵和强心药理学药物进行了最佳的血运重建和血流动力学支持，但仍发生了心源性休克。左心室辅助装置Impella LP 5.0（欧洲Abiomed有限公司）提供了额外的支持。植入后27小时，由于Impella流入部分急性血栓形成，装置发生故障。这一主要不良事件可能是由于心源性休克背景下的炎症状态、可能被吸入Impella内的既往存在的心室内血栓和/或抗凝治疗不足所致。关于这类并发症的数据非常少。因此，需要进一步研究来评估此类并发症的发生率以及避免它的方法。
